Repligen Announces CEO Transition Plan

Leadership Transition - Repligen Corporation announced the transition of Tony J. Hunt from CEO to Executive Chair, effective September 1, 2024, with Olivier Loeillot appointed as the new CEO [6] - The Board of Directors believes that this leadership succession plan will ensure the company's ongoing success and strategic vision [1][6] - Olivier Loeillot has nearly 30 years of industry experience, previously serving as Bioprocess President at Cytiva, overseeing a multi-billion dollar bioprocess portfolio [1][2] Company Performance - Under Tony Hunt's leadership, Repligen's revenue grew from approximately $63 million in 2014 to $639 million in 2023, reflecting an average annual growth rate of over 30% [2] - The company has achieved innovation leadership in bioprocessing through disciplined acquisitions, internal product development, and operational excellence [2] Future Outlook - Olivier Loeillot expressed enthusiasm for leading Repligen, highlighting the company's culture of innovation and commitment to excellence [7] - The Board is confident that Loeillot will build on the strong foundation established by Hunt and lead the company through its next growth phase [1][3]